Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25576437 | 0.84 | CA1 (0.39) | CA2SLC1A3SLC1A2SLC1A1CA1 | |
| SCHEMBL27861811 | 0.84 | GABRR1 (0.38) | MEN1GAAKMT2ASLC1A3SLC1A2 | |
| SCHEMBL13304967 | 0.84 | CA1 (0.44) | CA2MEN1GAAKMT2ACA1 | |
| SCHEMBL29264683 | 0.83 | CA2 (0.43) | CA2MAPK1MEN1GAAKMT2A | |
| SCHEMBL14064777 | 0.82 | MEN1 (0.36) | CA2MAPK1MEN1GAAKMT2A | |
| SCHEMBL14269087 | 0.82 | MEN1 (0.33) | CA2MAPK1MEN1GAAKMT2A | |
| SCHEMBL30499378 | 0.81 | ACE2 (0.45) | CA2MAPK1MEN1GAAKMT2A | |
| SCHEMBL28610755 | 0.81 | CA1 (0.49) | CA2MEN1GAAKMT2ACA1 | |
| SCHEMBL27705382 | 0.81 | CA2 (0.48) | CA2MAPK1MEN1GAAKMT2A | |
| SCHEMBL1803154 | 0.80 | CA2 (0.43) | CA2MAPK1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732177-B2 | Cement slurries, cured cement and methods of making and use of these | SAUDI ARABIAN OIL COMPANY (SA) | 2023-08-22 | — | — | US | disclosed |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CA2 2342/4885MAPK1 3995/4885MEN1 842/4885 |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | CA2 1677/4885MAPK1 4291/4885MEN1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.